Journal Mobile Options
Table of Contents
Vol. 80, No. 4, 2007
Issue release date: October 2007
Pharmacology 2007;80:269–278
(DOI:10.1159/000106447)

Inhibition of Epigallocatechin Gallate on Orthotopic Colon Cancer by Upregulating the Nrf2-UGT1A Signal Pathway in Nude Mice

Yuan J.-H. · Li Y.-Q. · Yang X.-Y.
Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, PR China

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Epigallocatechin gallate (EGCG), a key active ingredient in green tea, has many anti-carcinogenic activities. The aim of the present study was to investigate whether EGCG could prevent the occurrence or metastases of orthotopic colon cancer and probe the underlined mechanisms. We observed the inhibition of EGCG on growth and metastases of colon tumor implanted orthotopically in the cecum of nude mice. Immunohistochemistry and Western-blotting analysis were used to detect NF-E2-related factor 2 (Nrf2) protein expressions. RT-PCR was also applied to detect the mRNA levels of Nrf2, uridine 5′-diphosphate-glucuronosyltransferase (UGT) 1A, UGT1A8 and UGT1A10 in colon tumors. As a result, the inhibition rates on tumor growth in the 3 EGCG groups were significantly different (all p < 0.001) compared with the control group. In addition, different doses of EGCG were able to inhibit liver and pulmonary metastases to varying degrees. The protein level of Nrf2 and the mRNA levels of Nrf2, UGT1A, UGT1A8 and UGT1A10 significantly increased in EGCG-treated mice in comparison with the control group (all p < 0.01). The results demonstrated that EGCG has a preventive effect on the growth and liver and pulmonary metastases of orthotopic colon cancer in nude mice, and this anticancer effect could be partly caused by activating the Nrf2-UGT1A signal pathway.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Merrill RM, Kessler LG, Udler JM, Rasband GC, Feuer EJ: Comparison of risk estimates for selected diseases and causes of death. Prev Med 1999;28:179–193.
  2. Yang CS: Inhibition of carcinogenesis by tea. Nature 1997;389:134–135.
  3. Fujiki H, Suganuma M, Okabe S, Sueoka N, Komori A, Sueoka E, Kozu T, Tada Y, Suga K, Imai K, Nakachi K: Cancer inhibition by green tea. Mutat Res 1998;402:307–310.
  4. Mukhtar H, Ahmad N: Mechanism of cancer chemopreventive activity of green tea. Proc Soc Exp Biol Med 1999;220:234–238.
  5. Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Kuroishi T, Tominaga S: Tea and coffee consumption and the risk of digestive tract cancers: data from a comparative case-referent study in Japan. Cancer Causes Control 1998;9:209–216.
  6. Ji BT, Chow WH, Hsing AW, McLaughlin JK, Dai Q, Gao YT, Blot WJ, Fraumeni JF Jr: Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 1997;70:255–258.
  7. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY: A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003;97:1442–1446.
  8. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS: Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001;19:1830–1838.
  9. Lambert JD, Yang CS: Mechanisms of cancer prevention by tea constituents. J Nutr 2003;133:3262S–3267S.
  10. Conney AH: Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the 7th DeWitt S. Goodman Lecture. Cancer Res 2003;63:7005–7031.
  11. Park OJ, Surh YJ: Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicol Lett 2004;150:43–56.
  12. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS: Tea polyphenol (–)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563–7570.
  13. Peng G, Dixon DA, Muga SJ, Smith TJ, Wargovich MJ: Green tea polyphenol (–)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog 2006;45:309–319.
  14. Shimizu M, Deguchi A, Joe AK, Mckoy JF, Moriwaki H, Weinstein IB: EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 2005;5:69–78.

    External Resources

  15. Dashwood WM, Carter O, Al-Fageeh M, Li Q, Dashwood RH: Lysosomal trafficking of beta-catenin induced by the tea polyphenol epigallocatechin-3-gallate. Mutat Res 2005;591:161–172.
  16. Mojarrabi B, Mackenzie PI: Characterization of two UDP-glucuronosyltransferases that are predominantly expressed in human colon. Biochem Biophys Res Commun 1998;247:704–709.
  17. Venugopal R, Jaiswal AK: Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H: quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 1996;93:14960–14965.
  18. Kaderlik KR, Mulder GJ, Turesky RJ, Lang NP, Teitel CH, Chiarelli MP, Kadlubar FF: Glucuronidation of N-hydroxy heterocyclic amines by human and rat liver microsomes. Carcinogenesis 1994;15:1695–1701.
  19. Nowell SA, Massengill JS, Williams S, Radominska-Pandya A, Tephly TR, Cheng Z, Strassburg CP, Tukey RH, MacLeod SL, Lang PP, Kadlubar FF: Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo [4,5-b] pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved. Carcinogenesis 1999;20:1107–1114.
  20. Nugon-Baudon L, Rabot S, Szylit O, Raibaud P: Glucosinolate toxicity in growing rats: interactions with the hepatic detoxification system. Xenobiotica 1990;20:223–230.
  21. Wang M, Li YQ, Zhong N, Chen J, Xu XQ, Yuan MB: Induction of uridine 5′-diphosphate-glucuronosyltransferase gene expression by sulforaphane and its mechanism: experimental study in human colon cancer cells. Zhonghua Yi Xue Za Zhi 2005;85:819–824.
  22. Yang XY, Zhao WP, Li YQ, Sun ZY, Zhang Y, Guo YT, Yuan JH, Zhu Q, Wang M: The role of NF-E2-related factor 2 in the induction of uridine 5′-diphosphate-glucuronosyltransferase 1A and its isoforms by epigallocatechin gallate in colon cancer cells. Zhonghua Yi Xue Za Zhi 2006;86:82–87.
  23. Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, Kleeberger SR: Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002;26:175–182.
  24. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S: Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002;62:5196–5203.
  25. Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A, Lin W, Reddy B, Chan JY, Kong AN: Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci 2006;79:1944–1955.
  26. Shelby MK, Klaassen CD: Induction of Rat UDP-Glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways. Drug Metab Dispos 2006;34:1772–1778.
  27. Fu XY, Besterman JM, Monosov A, Hoffman RM: Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 1991;88:9345–9349.
  28. Giavazzi R, Campbell DE, Jessup JM, Cleary K, Fidler IJ: Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res 1986;46:1928–1933.
  29. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988;48:6863–6871.
  30. Fidler IJ: Critical factors in the biology of human cancer metastasis: 28th G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990;50:6130–6138.
  31. Wilmanns C, Fan D, O’Brian CA, Bucana CD, Fidler IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 1992;52:98–104.
  32. Terasawa H, Tanimura H, Nakamori M, Tsunoda T, Iwahashi M, Tani M, Yamaue H: Antitumor effect of interleukin-2 gene-modified fibroblasts for orthotopic colon cancer model. Jpn J Cancer Res 1999;90:1000–1006.
  33. Andreadi CK, Howells LM, Atherfold PA, Manson MM: Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol Pharmacol 2006;69:1033–1040.
  34. Wu CC, Hsu MC, Hsieh CW, Lin JB, Lai PH, Wung BS: Upregulation of heme oxygen-ase-1 by Epigallocatechin-3-gallate via the phosphatidylinositol 3-kinase/Akt and ERK pathways. Life Sci 2006;78:2889–2897.
  35. Li MH, Cha YN, Surh YJ: Peroxynitrite induces HO-1 expression via PI3K/Akt-dependent activation of NF-E2-related factor 2 in PC12 cells. Free Radic Biol Med 2006;41:1079–1091.
  36. Keum YS, Yu S, Chang PP, Yuan X, Kim JH, Xu C, Han J, Agarwal A, Kong AN: Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res 2006;66:8804–8813.
  37. Xu C, Yuan X, Pan Z, Shen G, Kim JH, Yu S, Khor TO, Li W, Ma J, Kong AN: Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol Cancer Ther 2006;5:1918–1926.
  38. Lee BS, Heo J, Kim YM, Shim SM, Pae HO, Kim YM, Chung HT: Carbon monoxide mediates heme oxygenase 1 induction via Nrf2 activation in hepatoma cells. Biochem Biophys Res Commun 2006;343:965–972.
  39. Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, Kleeberger SR: Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002;26:175–182.
  40. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S: Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002;62:5196–5203.
  41. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer N, Oostra BA, Lindhout D, Tytgat GNJ, Jansen PLM, Oude Elferink RPJ, Chowdhury NR: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert‘s syndrome. N Engl J Med 1995;333:1171–1175.
  42. Giuliani L, Ciotti M, Stoppacciaro A, Pasquini A, Silvestri I, De Matteis A, Frati L, Agliano AM: UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 2005;13:185–191.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50